James Armitage, M.D.
Professor of Medicine, Section of Oncology/Hematology, University of Nebraska Medical Center,
former President of ASCO

Dr. James O. Armitage has served as Chair of Internal Medicine, Dean of the College of Medicine at Nebraska and currently is the Joe Shapiro Professor of Medicine in the section of Oncology/Hematology. He developed and directed the Bone Marrow Transplant program at the University of Iowa and later at the University of Nebraska . Dr. Armitage is board certified in internal medicine, medical oncology, and hematology, a Fellow of both the American and Royal College of Physicians, a member of the National Cancer Advisory Board, and past president of both ASCO and the American Society of Blood and Marrow Transplantation.

Joseph Bertino, M.D.
Associate Director, Cancer Institute of New Jersey,
former President of AACR and ASCO

Dr. Joseph R. Bertino is currently Associate Director of the New Jersey Cancer Center and University Professor of Medicine and Pharmacology at UMDNJ-Robert Wood Johnson. Prior to his current position Dr. Bertino was Chairman of the Program of Molecular Pharmacology and Therapeutics at Memorial Sloan-Kettering Cancer Center and Professor of Medicine and Pharmacology at Cornell University Medical College. He spent many years at Yale University both as a Professor, Chief of Oncology and Chemotherapy and as the first Director of the Yale Comprehensive Cancer Center. Dr. Bertino is the past President of AACR and ASCO.

George Demetri, M.D.
Director, Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute,
Harvard Medical School

Dr. George Demetri is currently the Director of the Center for Sarcoma and Bone Oncology at Dana-Farber Cancer Institute. He led the clinical development and regulatory approval of Gleevec® for its indication of (GIST) gastrointestinal stromal tumor. Dr. Demetri's laboratory and clinical research focus is on the translation and clinical development of additional molecular-targeted agents in solid tumors.

Lawrence Einhorn, M.D.
Distinguished Professor of Medicine, Indiana University,
former President of ASCO

Dr. Lawrence Einhorn is Distinguished Professor of Medicine, Section of Hematology/Oncology, Indiana University Medical Center. He is a pioneer in combination chemotherapy, especially for testes cancer, where his work represents one of the most striking advances in cancer therapy. He has received many awards including the Kettering Prize in Cancer Research. He is Associate Editor for Medical and Pediatric Oncology, and Investigational New Drugs. Dr. Einhorn is a member of the National Academy of Sciences and past president of ASCO.

Alan Houghton, M.D.
Vice-Chairman of Department of Medicine
Memorial Sloan-Kettering Cancer Center


Dr. Houghton holds the Ludwig Chair in Clinical Investigation, and is Vice-Chairman of the Department of Medicine, Co-Head of the Melanoma Disease Management Team, and Head of the Laboratory of Tumor Immunology at Memorial Sloan-Kettering Cancer Center. He was the Chairman of Immunology at Sloan-Kettering and The Weill Graduate School of Biomedical Sciences of Cornell University (Sloan-Kettering Division) for 10 years, stepping down in 2004, and currently is a Professor of Medicine and Immunology at the Weill Medical and Graduate Schools of Cornell. He is also Chairman of the National Cancer Center Networks Melanoma Committee and Co-Chairman of the CALGB Melanoma Study Group of the national cooperative clinical trials group. Dr. Houghton was the first to demonstrate effectiveness of monoclonal antibody treatment for solid tumors and his laboratory has identified molecules and molecular targets on cancer cells that may be useful for therapy, many of which are currently being evaluated in clinical trials.

Alberto Pappo, M.D.
Professor of Pediatrics
Texas Children's Cancer Center

Dr. Alberto Pappo is Professor of Pediatrics at the Texas Children's Cancer Center. Dr. Pappo is world-renowned in the basic and clinical research of rare cancers, especially in the pediatric setting. He is the Chairman of the Rare Tumors Committee of the Children's Oncology Group. In his role as committee chair, Dr. Pappo has been instrumental in orphan drug development and novel clinical trial designs for rare cancer populations.

John F. Smyth, M.D.
Chair of Medical Oncology, University of Edinburgh Medical School,
President of ECCO, former President of ESMO

Dr John F. Smyth is Professor and Chairman of Medical Oncology, Head of the Cancer Research Centre, University of Edinburgh. His major research interest is the development and evaluation of new anti-cancer drugs. He is President of the Federation of European Cancer Societies, President of ECCO 2007, and former president of the European Society of Medical Oncology. He has published over 300 papers and is Editor-in-Chief of the European Journal of Cancer. He currently serves on the Expert Oncology Advisory Groups to the UK and European Drug Licensing Boards, and is a fellow of the Royal College of Physicians of Edinburgh and London, and fellow of the Royal Society of Edinburgh.

David Spriggs, M.D.
Head of Solid Tumor Oncology,
Memorial Sloan-Kettering Cancer Center

David Spriggs, MD, is currently Head of the Division of Solid Tumor Oncology in the Department of Medicine at Memorial Sloan-Kettering Cancer Center. He is the Winthrop Rockefeller Professor in Medical Oncology. He is an internationally known solid-tumor oncologist whose research focuses on the genetic regulation of drug resistance and new chemotherapy regimens. Dr. Spriggs is a physician-investigator in charge of translational research - linking clinical and laboratory observations together to better understand cancer and improve cancer treatment.